F	0	R	Μ	4

(Brint or Type Been

-
Check this box if no
longer subject to
Section 16. Form 4 or
Form 5 obligations
may continue. See
Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporti MARIO ERNEST	2. Issuer Name and Ticker or Trading Symbol Tonix Pharmaceuticals Holding Corp. [TNXP]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First C/O TONIX PHARMACE CORP., 509 MADISON A	JTICALS HOLDING	3. Date of Earliest T 06/20/2017	ransaction (Mont	th/Day/Ye	ear)	Officer (give title below) Officer (give title below)	ther (specify belo	ow)		
(Stree NEW YORK, NY 10022	4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)	Т	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Yea	/ /	ate, if Code (Instr. 8)		(A) or Disposed of (D) (Instr. 3, 4 and 5)		of (D)	Owned Following Reported Transaction(s)	6. Ownership Form:	Beneficial	
		(Month/Day/Year)	Code	v	Amount	(A) or (D)	Price		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)															
1. Title of	2.	3. Transaction	3A. Deemed	4. 5. Number		6. Date Exercisable and		7. Title and		8. Price of	9. Number of	10.	11. Nature		
Derivative	Conversion	Date	Execution Date, if	Transact	ransaction of		Expiration Date		Amount of		Derivative	Derivative	Ownership	of Indirect	
		(Month/Day/Year)		Code		Derivative		(Month/Day/Year)		Underlying		Security			Beneficial
× /	Price of		(Month/Day/Year)	(Instr. 8))	Securities						· /	-	Derivative	1
	Derivative				Acquired				(Instr. 3 and 4)					(Instr. 4)	
	Security				(A) or							0	Direct (D)		
					Disposed of							1	or Indirect		
					(D) (Instr. 3, 4,							Transaction(s) (Instr. 4)	(1) (Instr. 4)		
					(1130.5, 4, and 5)							(IIISU. 4)	(1130. 4)		
											Amount				
								Dete	Expiration		or				
								Date Exercisable	Date	Title	Number				
									Date		of				
				Code	V	(A)	(D)				Shares				
Stock	¢ 4 10	0(10010017				20.000		06/20/2010	06/20/2027	Common Stock	20.000	a a (1)	20.000	D	
Option	\$ 4.18	06/20/2017		А		20,000		06/20/2018	06/20/2027	Stock	20,000	\$ 0 (<u>1)</u>	20,000	D	

Reporting Owners

Demosting Ormers Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
MARIO ERNEST C/O TONIX PHARMACEUTICALS HOLDING CORP. 509 MADISON AVENUE, SUITE 306 NEW YORK, NY 10022	Х					

Signatures

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.